

# General Information

**Name of the Meeting**

The 11th Chronic Kidney Disease Frontier Meeting

**Date**

February 20 (Sun.), 2022

**Meeting Chair**

Shoichi Maruyama

Chairman of Advisory Committee of Chronic Kidney Disease Frontier Meeting

Department of Nephrology, Internal Medicine, Nagoya University Graduate School of Medicine

**Secretary General**

Tomoki Kosugi

Yoshinari Yasuda

Department of Nephrology / CKD Initiatives, Nagoya University Graduate School of Medicine

**Secretariat**

c/o Convention Linkage, Inc.

Asahiseimei Bldg., 3-32-20 Sakae, Naka-ku,

Nagoya, 460-0008 Japan

Phone: +81-52-262-5070

Fax: +81-52-262-5084

Email : [ckd@c-linkage.co.jp](mailto:ckd@c-linkage.co.jp)

## Information for Chairpersons and Speakers

You are required to participate in your session to be held on February 20th (Sun.), 2022 using the Zoom web conferencing system. Make sure to join a session at 30 minutes before it starts to confirm Zoom connection.

### For Speakers

Presentation Time

Designated Lectures : as informed in advance.

Oral Presentations : Presentation 8 min, Discussion 4 min

### Preparation of Presentation Data

1. All the presentations are required to be made using slide data as in general Zoom meetings.
2. You are recommended to prepare all of your presentation slides in 16:9 wide screen format. Though if you may use slides made in 4:3 format, the slides will not be displayed at full screen size (blank spaces will appear on both sides of the screen).
3. Please include the title of the presentation and your name, affiliation and other information on the first slide, and conclusion on the last slide.
4. When preparing slides, you are recommended to use the Windows OS, Microsoft PowerPoint 2010/2013/2016/2019 and the standard Windows fonts shown below.  
Japanese fonts: MS Gothic, MSP Gothic, MS Mincho, MSP Mincho, Meiryo  
English fonts: Times New Roman, Arial, Arial Black, Arial Narrow, Century, Century Gothic, Courier New, Georgia
5. The file name should be a combination of your session type and your name.  
(Example: Symposium1 TaroSuzuki.pptx)
6. Please keep the data size of slides to a minimum to ensure smooth streaming on Zoom.
7. Before starting your presentation, please connect the AC adaptor of your PC and turn off any screen saver and energy saver. (If you use a Macintosh, turn off the hot corner on the screen.)

### Presentation Language and Data

All presentations must be in English and all presentation data should be prepared in English.

# Program at a glance

## <The 11th Chronic Kidney Disease Frontier Meeting>

February 20 (Sun), 2022	
13:00	<p>13:00-13:05 <b>Opening Remarks</b></p> <p>13:05-13:53 <b>Oral Presentations</b> <b>&lt; Basic 1 &gt;</b> Chairs: Takaaki Abe, Hirokazu Okada O-1 ~ 4</p>
14:00	<p>13:55-14:25 <b>Sponsored Seminar 1</b> Sponsored by Chugai Pharmaceutical Co.,Ltd. Chair: Motoko Yanagita    Speaker: Naoki Nakagawa</p>
15:00	<p>14:35-15:25 <b>Oral Presentations</b> <b>&lt; Basic 2 &gt;</b> Chairs: Masafumi Fukagawa, Ichiei Narita O-5 ~ 8</p> <p>15:25-15:55 <b>Sponsored Seminar 2</b> Sponsored by Sumitomo Dainippon Pharma Co.,Ltd. Chair: Takashi Wada    Speaker: Akira Mima</p>
16:00	<p>16:05-17:05 <b>Oral Presentations</b> <b>&lt; Clinical &gt;</b> Chairs: Kunihiro Yamagata, Hitoshi Sugiyama O-9 ~ 13</p> <p>17:05-17:45 <b>Sponsored Seminar 3</b> Sponsored by Ono Pharmaceutical Co., Ltd. / AstraZeneca K.K. Chair: Naoki Kashihara    Speaker: Kei Fukami</p>
18:00	<p>17:55-18:40 <b>Controversy in the Treatment of Glomerulonephritis</b> Chairs: Masaomi Nangaku, Yon Su Kim Panelists: Li Zuo, Kearnat Praditpornsilpa, Chi-Chih Hung</p>
19:00	<p>18:40-19:25 <b>Invited Lecture</b> <b>Treatment of ANCA-Associated Vasculitis</b> Chair: Shoichi Maruyama Speaker: David Jayne</p> <p>19:25- <b>Closing Remarks</b></p>



# Program

13:05–13:53 **Oral Presentations**

**“Basic1”**

Chairs : Takaaki Abe (*Tohoku University School of Medical Sciences/Medicine, Japan*)

Hirokazu Okada (*Department of Nephrology, Saitama Medical University, Japan*)

**O-1 DZNEP, A HISTONE MODIFICATION INHIBITOR, SUPPRESSES RENAL FIBROSIS BY INHIBITING HIF1 A BINDING TO TIMP2 GENE THROUGH REDUCING OPEN CHROMATIN AREA**

Tomotaka Yamazaki, Imari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku  
*Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan*

**O-2 Advanced tertiary lymphoid tissues in protocol biopsies are associated with progressive graft dysfunction in kidney transplant recipients**

Yu Ho Lee<sup>1,2</sup>, Yuki Sato<sup>1,3</sup>, Mitsuru Saito<sup>4</sup>, Shingo Fukuma<sup>5</sup>, Masaya Saito<sup>6</sup>,  
Shigenori Yamamoto<sup>1,3</sup>, Atsushi Komatsuda<sup>6</sup>, Nobuhiro Fujiyama<sup>7</sup>, Shigeru Satoh<sup>7</sup>,  
Sang-Ho Lee<sup>8</sup>, Peter Boor<sup>9,10,11</sup>, Tomonori Habuchi<sup>4</sup>, Jürgen Floege<sup>10</sup>,  
Motoko Yanagita<sup>1,12</sup>

<sup>1</sup>*Department of Nephrology, Graduate School of Medicine, Kyoto University, Japan,*

<sup>2</sup>*Division of Nephrology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Republic of Korea,*

<sup>3</sup>*Medical Innovation Center TMK Project, Kyoto University, Japan,*

<sup>4</sup>*Department of Urology, Graduate School of Medicine, Akita University, Japan,*

<sup>5</sup>*Human Health Sciences, Graduate School of Medicine, Kyoto University, Japan,*

<sup>6</sup>*Department of Hematology, Nephrology, and Rheumatology, Graduate School of Medicine, Akita University, Japan,*

<sup>7</sup>*Center for Kidney Disease and Transplantation, Akita University Hospital, Japan,*

<sup>8</sup>*Division of Nephrology, Department of Internal Medicine, Kyung Hee University, Republic of Korea,*

<sup>9</sup>*Institute of Pathology, RWTH University of Aachen, Germany,*

<sup>10</sup>*Division of Nephrology, RWTH University of Aachen, Germany,*

<sup>11</sup>*Electron Microscopy Facility, RWTH University of Aachen, Germany,*

<sup>12</sup>*Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Japan*

**O-3 Profile of circulating microRNAs associated with hyperglycemia and their effect on kidney function decline in patients with type 2 diabetes**

Hiroki Kobayashi<sup>1,2</sup>, Eiichiro Satake<sup>2</sup>, Zaipul I. Md. Dom<sup>2</sup>, Masanori Abe<sup>1</sup>,  
Andrzej S. Krolewski<sup>2</sup>

<sup>1</sup>*Division of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Japan,*

<sup>2</sup>*Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA*

**O-4 Effects of sodium–glucose cotransporter 2 inhibitor, canagliflozin, on glomerular hyperfiltration and oxidative stress in mice with type 2 diabetes**

Megumi Kondo, Kengo Kidokoro, Hiroyuki Kadoya, Yoshihisa Wada,  
Hajime Nagasu, Tamaki Sasaki, Naoki Kashihara  
*Kawasaki Medical School, Japan*

**13:55-14:25 Sponsored Seminar 1**

Sponsored by Chugai Pharmaceutical Co.,Ltd.

Chair : Motoko Yanagita (*Department of Nephrology, Graduate School of Medicine, Kyoto University, Japan*)

**SS-1 Update on the treatment of refractory nephrotic syndrome**

Naoki Nakagawa

*Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan*

**14:35-15:25 Oral Presentations**

**“Basic2”**

Chairs : Masafumi Fukagawa (*Division of Nephrology, Endocrinology and Metabolism Tokai University School of Medicine, Japan*)

Ichiei Narita (*Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University, Japan*)

**O-5 Nicotinic acetylcholine receptor agonist reduces acute lung injury after renal ischemia-reperfusion injury by acting on splenic macrophages in mice**

Daiki Goto, Soichiro Nagata, Yoshitaka Naito, Shinsuke Isobe, Takamasa Iwakura, Tomoyuki Fujikura, Naro Ohashi, Akihiko Kato, Hideo Yasuda  
*First Department of Medicine, Hamamatsu University School of Medicine, Japan*

**O-6 Leukotriene B<sub>4</sub>-BLT1-dependent neutrophil recruitment contributes to the pathogenesis of crescent glomerulonephritis**

Ryotaro Shioda<sup>1,2</sup>, Airi Jo-Watanabe<sup>2,3</sup>, Toshiaki Okuno<sup>2</sup>, Kazuko Saeki<sup>2</sup>, Maiko Nakayama<sup>1</sup>, Takehiko Yokomizo<sup>2</sup>, Yusuke Suzuki<sup>1</sup>

<sup>1</sup>*Department of Nephrology, Juntendo University Faculty of Medicine, Japan,*

<sup>2</sup>*Department of Biochemistry, Juntendo University Graduate School of Medicine, Japan,*

<sup>3</sup>*AMED-PRIME, Japan Agency for Medical Research and Development, Japan*

**O-7 Hepatic phosphate uptake and hepatic afferent nerve transmission play pivotal roles in the maintenance of serum phosphate levels in a FGF23, PTH, and vitamin D independent manner**

Seiichi Yasuda, Kazunori Inoue, Atsuhiko Imai, Hiroki Okushima, Yusuke Katsuma, Ayumi Matsumoto, Isao Matsui, Yoshitaka Isaka  
*Department of Nephrology, Osaka University Graduate School of Medicine, Japan*

**O-8 Dietary magnesium insufficiency induces salt-sensitive hypertension in mice associated with reduced kidney COMT activity**

Asako Kumagai<sup>1</sup>, Keizo Kanasaki<sup>2</sup>

<sup>1</sup>*Department of Obstetrics and Gynecology, Juntendo University, Japan,*

<sup>2</sup>*Department of Internal Medicine I, Faculty of Medicine, Shimane University, Japan*

**15:25–15:55 Sponsored Seminar 2**

Sponsored by Sumitomo Dainippon Pharma Co.,Ltd.

Chair : Takashi Wada (*Department of Nephrology and Laboratory Medicine, Kanazawa University, Japan*)

**SS-2 Management of type 2 diabetes in diabetic kidney disease**

Akira Mima

*Department of Nephrology, Osaka Medical and Pharmaceutical University, Japan*

**16:05–17:05 Oral Presentations**

**“Clinical”**

Chairs : Kunihiko Yamagata (*Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan*)

Hitoshi Sugiyama (*Okayama University Hospital, Japan*)

**O-9 High chronicity index of the revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification of lupus nephritis is associated with increased risk of end-stage kidney disease: a retrospective single-center study**

Shiori Nakagawa<sup>1</sup>, Tadashi Toyama<sup>1,2</sup>, Yasunori Iwata<sup>1</sup>, Megumi Oshima<sup>1</sup>, Hisayuki Ogura<sup>1</sup>, Koichi Sato<sup>1</sup>, Yuta Yamamura<sup>1</sup>, Taro Miyagawa<sup>1</sup>, Shinji Kitajima<sup>1</sup>, Akinori Hara<sup>1,3</sup>, Norihiko Sakai<sup>1</sup>, Miho Shimizu<sup>1</sup>, Takashi Wada<sup>1</sup>

<sup>1</sup>*Department of Nephrology and Laboratory Medicine, Kanazawa University, Japan,*

<sup>2</sup>*Innovative Clinical Research Center, Kanazawa University Hospital, Japan,*

<sup>3</sup>*Department of Public Health, Kanazawa University, Japan*

**O-10 Increasing gender difference in the incidence of end-stage of renal disease in Okinawa**

Chisato Fukuhara<sup>1</sup>, Kentaro Kohagura<sup>2</sup>, Iseki Kunitoshi<sup>3</sup>

<sup>1</sup>*Department of Nephrology, Heartlife hospital, Japan,*

<sup>2</sup>*Dialysis Unit, University Hospital of the Ryukyus, Japan,*

<sup>3</sup>*Okinawa Heart and Renal Association, Japan*

**O-11 Long-term care needs and incidence of end-stage kidney disease: a retrospective cohort study**

Ryuichi Yoshimura<sup>1</sup>, Ryohei Yamamoto<sup>1</sup>, Maki Shinzawa<sup>2</sup>, Rie Kataoka<sup>3</sup>, Nami Ikeguchi<sup>3</sup>, Suzuna Kanda<sup>3</sup>, Yuki Nii<sup>3</sup>, Hiroshi Toki<sup>1</sup>, Toshiki Moriyama<sup>1</sup>

<sup>1</sup>*Health and Counseling Center, Osaka University, Japan,*

<sup>2</sup>*Department of Nephrology, Osaka University Graduate School of Medicine, Japan,*

<sup>3</sup>*Health Promotion Division, Neyagawa City Public Health Center, Japan*

**O-12 Urinary phenyl sulfate predict the 2-year ACR deterioration in a DKD cohort**

Koichi Kikuchi<sup>1</sup>, Ryota Kujirai<sup>3</sup>, Yotaro Matsumoto<sup>3</sup>, Koki Mise<sup>4</sup>, Tomohiro Nakamura<sup>2</sup>, Jun Wada<sup>4</sup>, Yoshihisa Tomioka<sup>3</sup>, Takaaki Abe<sup>1,5</sup>

<sup>1</sup>*Tohoku University Hospital, Japan,*

<sup>2</sup>*Tohoku Medical Megabank Organization, Tohoku University, Japan,*

<sup>3</sup>*Tohoku University Graduate School of Pharmaceutical Sciences, Japan,*

<sup>4</sup>*Okayama University, Japan,*

<sup>5</sup>*Tohoku University Graduate School of Biomedical Engineering, Japan*



**O-13 Performance of new CKD EPI equation without race among Japanese patients**

Yoshinari Yasuda<sup>1,2</sup>, Masaru Horio<sup>1</sup>, Enyu Imai<sup>1</sup>, Tsuyoshi Watanabe<sup>1</sup>,  
Akira Hishida<sup>1</sup>, Shoichi Maruyama<sup>2</sup>, Seiichi Matsuo<sup>1</sup>

<sup>1</sup>Study Group of developing the Japanese equation for estimated GFR, Japan.

<sup>2</sup>Department of Nephrology, Nagoya University Graduate School of Medicine, Japan

**17:05-17:45 Sponsored Seminar 3**

Sponsored by Ono Pharmaceutical Co., Ltd. / AstraZeneca K.K.

Chair : Naoki Kashihara (*Division of Nephrology and Hypertension, Kawasaki Medical School, Japan*)

**SS-3 SGLT2 inhibitor as a promising therapeutic strategy for chronic kidney disease**

Kei Fukami

*Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan*

**17:55-18:40 Controversy in the Treatment of Glomerulonephritis**

Chair : Masaomi Nangaku (*Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine, Japan*)

Yon Su Kim (*Seoul National University College of Medicine, Republic of Korea*)

**Panelists** Li Zuo

*Peking University First Hospital, China*

Kearkiat Praditpornsilpa

*Chulalongkorn University, Thailand*

Chi-Chih Hung

*Kaohsiung Medical University, Taiwan*

**18:40-19:25 Invited Lecture**

Chair : Shoichi Maruyama (*Department of Nephrology, Internal Medicine, Nagoya University Graduate School of Medicine, Japan*)

**IL-1 Treatment of ANCA-Associated Vasculitis**

David Jayne

*University of Cambridge, UK*

**19:25- Closing Remarks**